Welcome to our dedicated page for Alpha Tau Medical Ltd. SEC filings (Ticker: DRTSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alpha Tau Medical Ltd.'s SEC filings document foreign private issuer reports for a clinical-stage oncology company developing Alpha DaRT for solid tumors. Recent Form 6-K reports furnish press releases and company presentations covering clinical data, trial progress, regulatory submissions, and conference-call materials for programs such as ReSTART in recurrent cutaneous squamous cell carcinoma and REGAIN in recurrent glioblastoma.
The filings also identify disclosure mechanics for furnished exhibits, incorporation by reference into registration statements, and Exchange Act treatment of company presentations and press releases. For this issuer, the filing record centers on clinical-development disclosures, FDA-related PMA and IDE context, regulatory-risk language, capital-market registration references, and public-company reporting obligations.